Accumulating evidence suggests that integrase strand-transfer inhibitors (INSTI)-based initial antiretroviral therapy (ART) results in greater CD4/CD8 ratio recovery compared to other regimens. However, it is unknown whether the treatment initiation with INSTI-based two-drug regimens (2DR) has a different impact on the CD4/CD8 ratio recovery compared to INSTI-based 3DR.
We emulated a target trial to assess the effect of two different ART strategies on CD4/CD8 ratio normalization. We included all subjects included in the Cohort of the Spanish HIV Research Network (CoRIS) who started 2DR with dolutegravir (DTG) plus 3TC or 3DR based on bictegravir or DTG. We matched each participant who started 2DR with up to four participants who received 3DR based on age, sex, transmission category, educational level, country of origin, baseline HIV RNA, AIDS diagnosis, and pre-ART nadir CD4/CD8 ratio. Subsequently, we fitted generalized estimating equation (GEE) models to allow for clustered data analysis, to assess the risk of CD4/CD8 ratio normalization at 48 weeks for three different cutoffs (0.5, 1.0 and 1.5).
A total of 485, 805, and 924 participants were matched for each of the three analyses (cutoffs of 0.5, 1.0, and 1.5, respectively). The distribution of covariates was similar in the three models. Overall, the study sample was representative of a medium-aged population (median age 37 years) with a higher representation of men (88%) and a median CD4/CD8 ratio around 0.30. No participant presented virological failure during follow-up. At 48 weeks, 45% of participants achieved a CD4/CD8 ratio >0.5, 15% achieved a ratio >1.0, and 6% achieved a ratio >1.5 (Figure 1). After matching according to the covariates of interest, GEE models yielded a similar risk of reaching a CD4/CD8 ratio >0.5 (OR 1.00, 95% CI 0.67 – 1.50), CD4/CD8 >1.0 (OR 1.03, 95% CI 0.68 – 1.58), and CD4/CD8 >1.5 (OR 0.86, 95% CI 0.48 – 1.54) between both treatment strategies. Figure 1 shows Kaplan-Meier survival plots of estimated overall CD4/CD8 normalization. There were no differences between 2DR and 3DR in the incidence ratio of CD4/CD8 ratio normalization at any of the cutoffs.
This study provides new evidence that CD4/CD8 ratio recovery rates are similar during the first 48 weeks after ART initiation with 2DR or 3DR INSTI-based therapies. Next studies should address the potential long-term differences between these strategies.